Sanofi probed for possible market manipulation by French prosecutor: Source

Published On 2023-11-09 11:22 GMT   |   Update On 2023-11-11 16:34 GMT
Advertisement

Paris: French financial prosecutors have opened a preliminary probe into drugmaker Sanofi over possible share price manipulation, a person close to the investigation said on Tuesday, while the company said it was unaware of any criminal investigation into its past financial reporting.

The person close to the investigation confirmed earlier reports from French media La Lettre and news agency AFP, which said a preliminary probe was opened in March and was linked to possible market manipulation caused by the group's past financial communication.

La Lettre reported the investigation was linked to Sanofi's communication around the launch of its blockbuster drug Dupixent in 2017.

"As a listed company, the financial informations published by Sanofi are accurate, precise and sincere, and are duly audited by two auditing firms," Sanofi said in an emailed statement.

It said it was "not aware of any preliminary investigation by the Parquet National Financier on its 2017 accounts or of any other investigation", adding it reserved the right to take legal action against any false or defamatory allegations.

Read also: Sanofi considers listing consumer unit late next year




Tags:    
Article Source : Reuters

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News